The Obesity Association™, a division of the American Diabetes Association®, (Obesity Association), with inaugural support from Novo Nordisk Inc., is taking the next step toward improved obesity care.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

The sudden departure of Novo Nordisk chief executive Lars Fruergaard Jørgensen comes not amid scandal or strategic calamity, ...

Thammasat University Hospital, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. (“Novo Nordisk”), announced a ...